STOCK TITAN

Adc Therapeutics SA - ADCT STOCK NEWS

Welcome to our dedicated news page for Adc Therapeutics SA (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics SA.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adc Therapeutics SA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adc Therapeutics SA's position in the market.

Rhea-AI Summary
ADC Therapeutics SA (ADCT) to host conference call and webcast to report Q2 2023 financial results and business updates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
conferences earnings
-
-
Rhea-AI Summary
ADC Therapeutics SA (NYSE: ADCT) to discontinue Phase 2 LOTIS-9 clinical trial for ZYNLONTA® and rituximab in unfit or frail patients with previously untreated DLBCL due to challenges in defining the addressable segment and the benefit-risk profile not supporting continuation. FDA places partial clinical hold on trial for new patient enrollment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.33%
Tags
Rhea-AI Summary
ADC Therapeutics has announced a voluntary pause in the enrollment of new patients in the Phase 2 LOTIS-9 clinical trial evaluating ZYNLONTA and rituximab in unfit or frail patients with previously untreated diffuse large B-cell lymphoma. The pause was initiated due to potentially excessive respiratory-related events, including seven Grade 5 fatal events and five Grade 3 or Grade 4 respiratory-related TEAEs. The cause of these events is under investigation. All patients with fatal events had significant underlying respiratory and/or cardiac co-morbidities and were over 80 years old.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.94%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.6%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
Adc Therapeutics SA

NYSE:ADCT

ADCT Rankings

ADCT Stock Data

366.43M
62.97M
29%
41.17%
1.2%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Switzerland
Epalinges

About ADCT

adc therapeutics is a biotechnology company located in lausanne, vaud, switzerland.